Raymond James lowered the firm’s price target on Trevi Therapeutics (TRVI) to $27 from $29 and keeps a Strong Buy rating on the shares. The firm believes Haduvio is the most efficacious treatment in clinical development for both IPF-chronic cough and refractory chronic cough, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI:
- Promising Phase 2b Results and Strong Financial Position Drive Buy Rating for Trevi Therapeutics
- Trevi Therapeutics Reports Positive Trial Results and Financial Stability
- Trevi Therapeutics reports Q2 EPS (9c), consensus (10c)
- Trevi Therapeutics initiated with an Overweight at Cantor Fitzgerald
- Trevi Therapeutics Stockholders Approve Key Amendments